Navigation Links
ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Date:1/6/2009

nefit of identifying epitopes that are particularly disease specific, thus enabling the discovery of safer drugs with fewer side effects. In addition, such epitopes may provide the opportunity to create new intellectual property, even in more heavily investigated areas.

"We are very pleased to expand further our successful and longstanding collaboration with Allergan. We believe that combining the capabilities of our two organizations and enlarging both the research and commercial scope will enhance our ability to create value for our shareholders," said Loic Maurel, CEO of ExonHit Therapeutics.

The agreement provides for revised commercial terms. It expands Allergan's rights when sublicensing compounds discovered in the course of the collaboration with ExonHit. In return, ExonHit will receive from Allergan upfront payments as well as payments linked to developmental milestones and sales achievements. ExonHit will also be paid royalties on future sales.

Detailed financial terms were not disclosed.

About ExonHit Therapeutics

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit Therapeutics has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit Therapeutics has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.<
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015 BioRx, a Diplomat company (NYSE: ... a Top Workplace in 2015 based on a survey held ... Media Group and a Philadelphia -based research ... and was completed by employees across the Greater ... area, with topics ranging from workplace environment to overall organizational ...
(Date:7/7/2015)... 7, 2015 Hill-Rom,s recent announcement that ... in cash and stock means the company can ... to Kalorama Information. The healthcare market researcher said ... device and advanced wound care markets, and is ... lifting devices, and other healthcare equipment. Welch Allyn,s ...
(Date:7/7/2015)... --  ICD-10 Charts ( www.icd10charts.com ) announced today ... officially launched its newest line of ICD-10 preparation ... new 4 Step ICD-10 Implementation Plan.  Both of ... Charts resources and mobile apps, are available to ... the release of these resources, the company has ...
Breaking Medicine Technology:BioRx Named a Top Workplace in 2015 by Enquirer Media 2BioRx Named a Top Workplace in 2015 by Enquirer Media 3Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4
... WIRE)--May 15, 2007 - Synthetic Blood,International, Inc. ... analysis of its Phase IIa study with ... line with preliminary,study results announced in December ... of increasing patients' oxygen,tension levels compared with ...
... WIRE)--May 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SLXP) today ... the Company's products,will be presented at Digestive Disease ... Digestive Disease Week is considered the,largest and most ... Every year it attracts more than 16,000 physicians,researchers ...
Cached Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:7/7/2015)... ... July 07, 2015 , ... An article published June ... how innovation and technology would be the “key factors” in the growth of ... accessibility and affordability, especially in emerging and growing markets. According to the compounding ...
(Date:7/7/2015)... BELLINGHAM, WA (PRWEB) , ... July 07, 2015 , ... ... set to break ground as early as Summer 2015 on a four-acre site in ... dollar project, with the support of city officials and other members of the local ...
(Date:7/7/2015)... , ... July 07, 2015 ... ... convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, ... program, surpassing their original 2015 fundraising goal by nearly $100,000, to help ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... Times highlights rumors about possible facial rejuvenation that have emerged about Hillary Clinton. ... U.S. Secretary of State looks more youthful than she has in some time ...
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased to announce the ... York 11747. The new facility is a state of the art building, located ... Quadrino, the firm's CEO and founder, said, "We are pleased to service our clients ...
Breaking Medicine News(10 mins):Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 2Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 3Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3
... of the Phase 2,clinical trial of R788 (fostamatinib ... lymphoma (NHL) will be presented today at a,plenary ... Hematology (ASH),Meeting. The results affirm preliminary reports ... patients and shows therapeutic benefit in,patients suffering from ...
... weight, instead of dieting, is a good way to keep ... News) -- The holiday season is always extra challenging for ... in the fun without packing on the pounds. , ... Brigham and Women,s Hospital in Boston, recommends trying to simply ...
... December 7, 2008) The largest study ever to ... prevent deadly blood clots in patients with cancer undergoing ... on Sunday, December 7, at 9:30 a.m., during the ... in San Francisco, CA. Additional research being featured at ...
... (SAN FRANCISCO, December 6, 2008) A study assessing the ... a variety of hospital settings will be presented at a ... the 50th Annual Meeting of the American Society of Hematology ... that help determine stroke risk in children with sickle cell ...
... The United States can learn from the Dutch Health Insurance ... Ph.D., in the December issue of the Journal of ... management, policy and community health at The University of Texas ... which discusses universal health care coverage in the Netherlands and ...
... create partnerships with pediatric research institutions around the globe, ... understanding with the department of pediatrics at Tokyo,s Jikei ... the first among Mattel Children,s Hospital,s many planned agreements ... , Signed last month, the UCLAJikei ...
Cached Medicine News:Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 2Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 3Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 4Health News:Holidays Don't Have to Make You Heavier 2Health News:Research highlights new approaches to prevent blood clots 2Health News:Research highlights new approaches to prevent blood clots 3Health News:Research highlights new approaches to prevent blood clots 4Health News:Research highlights new approaches to prevent blood clots 5Health News:Research highlights new approaches to prevent blood clots 6Health News:Research highlights new approaches to prevent blood clots 7Health News:Research highlights new approaches to prevent blood clots 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:UT public health policy expert says US can learn from Dutch universal healthcare coverage 2
... Impulse II lead series are silicon ... extend the longevity of the pacemaker ... The high impedance of the lead ... electrode surface, combined with the elution ...
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Selute Picotip Atrial-J steroid eluting passive fixation lead...
Medicine Products: